News for Healthier Living

Personalized Breast Cancer Treatment through Non-Invasive Liquid Biopsy

In patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer, the molecular classification of their case plays a pivotal role in the formulation of personalized treatment plans aimed at optimizing outcomes. Despite notable advancements in this field, significant challenges persist. Issues such as pre-analytical variability, interpretative ambiguity, and inconsistent threshold definitions hinder accurate diagnosis and subsequent treatment decisions. In this context, emerging liquid biopsy technologies present a promising solution.

November 14, 2024


November 19 2024

November 18 2024

November 17 2024

November 16 2024

November 15 2024

November 14 2024

November 13 2024

November 12 2024

November 11 2024

November 10 2024

November 9 2024

November 8 2024

November 7 2024

November 6 2024

November 5 2024